In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST).

Abstract

Table 2. In vitro activity of tigecycline against molecularly characterized MDR isolates collected from tigecycline phase III cSSSI and cIAI clinical trials and the TEST global surveillance program; frequency distribution (N) and cumulative percent inhibited at each MIC (mg/L). Table 1. In vitro activity of tigecycline against molecularly characterized MDR isolates collected from patients enrolled in tigecycline phase III cSSSI and cIAI clinical trials; frequency distribution (N), cumulative percent inhibited at each MIC (mg/L), and clinical response at Test of Cure. Background: The Tigecycline Evaluation Surveillance Trial (TEST) monitors activity of tigecycline (TIG) and comparators against clinical pathogens collected globally. TIG is a glycylcycline approved for treatment of complicated skin and skin structure and intra-abdominal infections (cSSSI and cIAI). Abstract